• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Pitfalls at Chemistry of Adenoviral Vector Vaccine against COVID-19 and How to Circumvent it.新型冠状病毒腺病毒载体疫苗的化学陷阱及其规避方法。
Adv Pharm Bull. 2022 Mar;12(2):217-218. doi: 10.34172/apb.2022.024. Epub 2021 Aug 7.
2
Colchicine May Interfere With the Efficacy of the Adenoviral Vector-Based Vaccine for COVID-19.秋水仙碱可能会干扰基于腺病毒载体的COVID-19疫苗的疗效。
Clin Med Insights Arthritis Musculoskelet Disord. 2022 Mar 23;15:11795441221081061. doi: 10.1177/11795441221081061. eCollection 2022.
3
Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.通过使用异源E1缺失腺病毒疫苗载体的初免-加强方案诱导CD8 + T细胞针对HIV-1抗原的反应。
J Immunol. 2003 Dec 15;171(12):6774-9. doi: 10.4049/jimmunol.171.12.6774.
4
Development of nonhuman adenoviruses as vaccine vectors.非人腺病毒作为疫苗载体的研发。
Vaccine. 2006 Feb 13;24(7):849-62. doi: 10.1016/j.vaccine.2005.08.101. Epub 2005 Sep 23.
5
An adenoviral vector-based mucosal vaccine is effective in protection against botulism.基于腺病毒载体的黏膜疫苗能有效预防肉毒中毒。
Gene Ther. 2009 Mar;16(3):367-75. doi: 10.1038/gt.2008.181. Epub 2009 Jan 8.
6
A rapid strategy for constructing novel simian adenovirus vectors with high viral titer and expressing highly antigenic proteins applicable for vaccine development.一种快速构建具有高病毒滴度和表达高抗原性蛋白的新型猿猴腺病毒载体的策略，适用于疫苗开发。
Virus Res. 2019 Jul 15;268:1-10. doi: 10.1016/j.virusres.2019.05.008. Epub 2019 May 17.
7
Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines.用于开发下一代流感疫苗的基于腺病毒载体的疫苗平台。
Vaccines (Basel). 2020 Oct 1;8(4):574. doi: 10.3390/vaccines8040574.
8
Use of the cosmid adenoviral vector cloning system for the in vitro construction of recombinant adenoviral vectors.使用黏粒腺病毒载体克隆系统进行重组腺病毒载体的体外构建。
Hum Gene Ther. 1997 Jul 20;8(11):1321-30. doi: 10.1089/hum.1997.8.11-1321.
9
Progress in Adenoviral Capsid-Display Vaccines.腺病毒衣壳展示疫苗的进展
Biomedicines. 2018 Jul 26;6(3):81. doi: 10.3390/biomedicines6030081.
10
Extended tropism of an adenoviral vector does not circumvent the maturation-dependent transducibility of mouse skeletal muscle.
J Gene Med. 1999 Nov-Dec;1(6):393-9. doi: 10.1002/(SICI)1521-2254(199911/12)1:6<393::AID-JGM65>3.0.CO;2-U.

引用本文的文献

1
An Overview of the Use of Nanoparticles in Vaccine Development.纳米颗粒在疫苗研发中的应用概述
Nanomaterials (Basel). 2023 Jun 9;13(12):1828. doi: 10.3390/nano13121828.
2
Pregnant and Breastfeeding Mothers Who Have Received the ChAdOx1 AstraZeneca COVID-19 Vaccine May Have Infants with an Increased Risk of Zinc Insufficiency and SCID Disease.接种过阿斯利康ChAdOx1新冠疫苗的孕妇和哺乳期母亲所生婴儿可能患锌缺乏症和重症联合免疫缺陷病（SCID）的风险增加。
Adv Pharm Bull. 2023 Mar;13(2):216-217. doi: 10.34172/apb.2023.024. Epub 2022 Apr 4.
3
Non-replicative antibiotic resistance-free DNA vaccine encoding S and N proteins induces full protection in mice against SARS-CoV-2.编码 S 和 N 蛋白的非复制性抗生素耐药性免费 DNA 疫苗可在小鼠中诱导针对 SARS-CoV-2 的完全保护。
Front Immunol. 2022 Nov 9;13:1023255. doi: 10.3389/fimmu.2022.1023255. eCollection 2022.

本文引用的文献

1
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.接种 ChAdOx1 nCov-19 疫苗后发生血栓性血小板减少症。
N Engl J Med. 2021 Jun 3;384(22):2092-2101. doi: 10.1056/NEJMoa2104840. Epub 2021 Apr 9.
2
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.在一项 1/2 期临床试验中，单次接种 ChAdOx1 nCoV-19（AZD1222）疫苗诱导的 T 细胞和抗体反应。
Nat Med. 2021 Feb;27(2):270-278. doi: 10.1038/s41591-020-01194-5. Epub 2020 Dec 17.
3
A case of EDTA-dependent pseudothrombocytopenia: simple recognition of an underdiagnosed and misleading phenomenon.一例乙二胺四乙酸（EDTA）依赖性假性血小板减少症：对一种诊断不足且具有误导性现象的简单识别
BMC Clin Pathol. 2014 May 1;14:19. doi: 10.1186/1472-6890-14-19. eCollection 2014.
4
Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide.用合成聚合物修饰腺病毒基因转移载体：科学综述与技术指南。
Mol Ther. 2008 Jan;16(1):16-29. doi: 10.1038/sj.mt.6300321. Epub 2007 Oct 2.
5
Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance.腺病毒诱导的血小板减少症：血管性血友病因子和P选择素在介导血小板加速清除中的作用。
Blood. 2007 Apr 1;109(7):2832-9. doi: 10.1182/blood-2006-06-032524.
6
Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone.通过腺病毒载体聚乙二醇化和甲基强的松龙消除先天性免疫反应和肝脏炎症。
Hum Gene Ther. 2005 Dec;16(12):1439-51. doi: 10.1089/hum.2005.16.1439.
7
Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses.评估聚乙二醇对第一代腺病毒载体和辅助依赖型腺病毒载体的修饰以降低先天性免疫反应。
Mol Ther. 2005 Jan;11(1):66-79. doi: 10.1016/j.ymthe.2004.09.015.
8
That zincing feeling: the effects of EDTA on the behaviour of zinc-binding transcriptional regulators.那种锌的感觉：乙二胺四乙酸对锌结合转录调节因子行为的影响
Biochem J. 2004 Aug 1;381(Pt 3):e3-4. doi: 10.1042/BJ20041096.
9
The CBP/p300 TAZ1 domain in its native state is not a binding partner of MDM2.处于天然状态的CBP/p300 TAZ1结构域不是MDM2的结合伴侣。
Biochem J. 2004 Aug 1;381(Pt 3):685-91. doi: 10.1042/BJ20040564.
10
Intravenous administration of replication-incompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing in vivo platelet clearance.给恒河猴静脉注射无复制能力的腺病毒会通过增加体内血小板清除率而导致血小板减少。
Br J Haematol. 2003 Dec;123(5):903-5. doi: 10.1046/j.1365-2141.2003.04719.x.

Pitfalls at Chemistry of Adenoviral Vector Vaccine against COVID-19 and How to Circumvent it.

作者信息

Ahmed Amr, Nezami Mohammad, Alkattan Abdullah

机构信息

Department of Public Health, Tuberculosis Program, First Health Cluster, Ministry of Health, Riyadh, Saudi Arabia.

President and CEO of Sahel Oncology LLC, Orange Coast Medical Center of Hope Inc. 496 Old Newport Blvd. #7 Newport Beach, CA 92612, USA.

出版信息

Adv Pharm Bull. 2022 Mar;12(2):217-218. doi: 10.34172/apb.2022.024. Epub 2021 Aug 7.

DOI:10.34172/apb.2022.024
PMID:35620347
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9106963/
Abstract
摘要